$AMGN , the second-largest holding in $SCHD, delivered a strong Q2. β EPS: $6.29 (beat by $0.67) β Revenue: $10.1B (+10% YoY, beat by $680M) Key highlights: π’ Product sales increased 9%, driven by higher volumes. π’ 22 products posted double-digit sales growth. π’ 17 products are now generating annual sales above $1B. Updated 2026 Outlook π Revenue: $38.2Bβ$39.4B, ahead of the ~$37.7B consensus. π Non-GAAP EPS: $22.30β$23.50. π° Up to $3.0B in share repurchases. Shares initially rallied after the earnings release before giving back most of those gains in after-hours trading. Overall, another solid quarter from one of $SCHDβs largest holdings.
1,282 views
1 Comments
Scott S@scottsinvesting Β· 20d
Thanks for sharing Cooper... I own $AMGN and $SCHD for that matter and honestly forgot Amgen was having earnings today. I've owned it for a very long time now and admittedly don't pay nearly as close attention to it as I should considering how much I own.
See the full comment section πSign up for the full Blossom experience!